URGN: Falling Wedge detected on 21 Oct 2026

URGN is forming a falling wedge pattern with excellent structural quality (15.0/15 structure score). The stock trades at $35.01, pinned between support at $30.37 and resistance at $36.12. The breakout score of 11.92 indicates high probability of upside movement with a conservative target of $36.67—just above current resistance. Volume score of 7.0 signals weak volume confirmation, typical during consolidation. RSI at 31.89 suggests oversold conditions, historically favorable for wedge reversals. The pattern captures a stock down 18.96% over one month but positioned 113.93% above its 52-week low, indicating capitulation-phase consolidation.

On October 19, 2026, UroGen Pharma announced that the FDA accepted its marketing application for UGN-103, a novel sustained-release formulation of mitomycin targeting adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. On October 19, 2026, UroGen Pharma received a reiteration of its Buy rating from HC Wainwright & Co., with the price target remaining unchanged at $75.00. ZUSDURI grew 109% quarter-over-quarter; JELMYTO generated $21.7M (+7% YoY). The falling wedge coincides with both a major regulatory milestone (FDA acceptance) and analyst validation. The biotech sector regime is bullish (+0.9), creating tailwinds for oncology assets, while the broader market remains neutral (-0.18), suggesting URGN's setup hinges on company-specific catalysts rather than sector rotation.

A successful breakout above $36.12 resistance with volume acceleration would signal continuation toward the $36.67 conservative target, with measured move potential extending to $50+. Historical falling wedge patterns in this volatility environment (6.51% ATR) show 75.44% win probability. Invalidation occurs decisively below key support at $30.37, which would negate the bullish setup and represent a 13.3% downside risk. Traders should require volume expansion above the 1.06M 20-day average (current volume is 747K, 0.7x normal) to confirm pattern integrity. The wedge narrows into its apex over the next 5-10 trading days.

Volume deterioration (current 0.7x average) weakens conviction; breakout without volume surge could fade. MACD histogram is negative (-0.424), suggesting momentum lags price. Recent insider Form 4 filings (October 9, 2026) warrant review for selling pressure. Beta of 0.8 provides some defensive qualities but limits upside participation if broader biotech rally accelerates. FDA approval timing for UGN-103 remains unspecified—regulatory delay beyond Q4 2026 could trigger sharp reversals. With market cap at $1.7B and event-driven valuation, any clinical setback or competitive commentary could break support swiftly. The stock's 31.89 RSI is oversold but not extreme; further compression below 25 signals capitulation risk rather than opportunity.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.